In this insightful session, Dr. Erik Alexander, Brigham and Women’s Hospital, explores the transformative role of molecular markers in improving thyroid cancer care. Discussing the prognostic significance of genomic tools, Dr. Alexander highlights how advancements in RNA expression analysis are helping clinicians better understand tumor behavior and recurrence risk.
While the journey to fully unravel the molecular mechanisms of thyroid cancer is ongoing, the integration of genomic insights is shaping more personalized, effective care strategies for patients. Dr. Alexander emphasizes the importance of moving beyond single gene mutations, which often lack independent predictive power, to focus on the broader insights offered by RNA expression. Clinicians can then categorize thyroid cancers into meaningful expression groups and gain actionable insights to guide patient-specific treatment plans.
Listen in as he shares his perspective on how integrating prognostic genomic data improves diagnostic accuracy and empowers better decision-making to improve patient outcomes.
Working together with the cancer research community, our mission is to advance thyroid cancer care with exceptional genomic testing for personalized treatment planning.
Key topics
- 0:00 – Introduction
- 2:00 – The Complexity of Single Gene Mutations
- 3:00 – What Happens if you Look for Mutations
- 6:00 – Cellular Biology: Multiple Molecular Targets
- 7:00 – Translation Into Clinical Care
- 8:00 – Molecular Testing: Diagnostics
- 18:00 – The Power of RNA Expressions
- 23:00 – Three Prognostic Categories
- 25:00 – Prognostic Opportunities Ahead
- 28:00 – Conclusion: Molecular Prognostics & Thyroid Cancer Care
Speakers
Erik Alexander, M.D.
Brigham and Women’s Hospital
Tags
On Demand
Afirma Thyroid